Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 41Central Nervous System Neoplasms 32Gliosarcoma 29Brain Neoplasms 28Astrocytoma 28Glioma 20Oligodendroglioma 16Ependymoma 6Medulloblastoma 4Neuroectodermal Tumors, Primitive 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Familial ependymoma 2Choroid Plexus Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vasculitis, Central Nervous System 1Testicular Neoplasms 1Stiff-Person Syndrome 1

Interventions

Waiting Lists 1Streptozocin 1Radiosurgery 1Radiation 1Mercaptopurine 1Circulating Tumor DNA 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Diseases, Inborn × Carmustine × CNS × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡